AN2 Therapeutics Stock Quote ANTX - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

2.86

Bid

2.82

Ask

2.86

Volume

63,077

2.70 Day's Range 2.8999

1.91 52 Week Range 22.22

Market Cap

83.223M

Previous Close

2.79

Open

2.80

Last Trade

2.82

Last Trade Time

Financial Volume

$ 174,182

VWAP

2.7614

Average Volume (3m)

145,051

Shares Outstanding

29,829,040

Dividend Yield

PE Ratio

-1.34

Earnings Per Share (EPS)

-2.17

Revenue

Net Profit

-64.73M

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.an2therapeutics.com

Headquarters

Dover, Delaware, USA

Founded

1970

AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was $2.79. Over the last year, AN2 Therapeutics shares have traded in a share price range of $ 1.91 to $ 22.22.

AN2 Therapeutics currently has 29,829,040 shares outstanding. The market capitalization of AN2 Therapeutics is $83.22 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -1.34.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.28	10.8527131783	2.58	3.07	2.49	130242	2.83763205	CS
4	0.77	36.8421052632	2.09	3.07	2.02	167890	2.59708174	CS
12	0.52	22.2222222222	2.34	3.07	1.91	145051	2.31211571	CS
26	-15.77	-84.6484165325	18.63	21.4	1.91	320070	3.77068885	CS
52	-4.98	-63.5204081633	7.84	22.22	1.91	196194	6.28440657	CS
156	-13.99	-83.0267062315	16.85	23.58	1.91	119243	7.69911986	CS
260	-13.99	-83.0267062315	16.85	23.58	1.91	119243	7.69911986	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	158.14M
CMAXCareMax Inc	$ 5.19 (228.48%)	102.64M
NUKKNukkleus Inc	$ 0.499 (55.94%)	26.2M
SNOASonoma Pharmaceuticals Inc	$ 0.423 (37.34%)	4.88M
ONDSOndas Holdings Inc	$ 1.1297 (34.06%)	2.19M
LGCBLinkage Global Inc	$ 3.6601 (-29.82%)	168k
CGBSCrown LNG Holdings Ltd	$ 0.9997 (-29.10%)	3.39M
SPECSpectaire Holdings Inc	$ 0.3962 (-24.53%)	1.87M
GSUNGolden Sun Health Technology Group Ltd	$ 5.13 (-23.66%)	158.79k
PSNLPersonalis Inc	$ 2.9808 (-22.58%)	3.11M
NVDANVIDIA Corporation	$ 123.54 (4.76%)	239M
SQQQProShares UltraPro Short QQQ	$ 8.09 (-4.37%)	183.65M
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	158.14M
SERVServe Robotics Inc	$ 8.73 (15.63%)	151.56M
NCPLNetcapital Inc	$ 0.1118 (7.50%)	124.37M